MX2012001708A - Anticuerpo humanizado anti-oligomero de amiloide b. - Google Patents
Anticuerpo humanizado anti-oligomero de amiloide b.Info
- Publication number
- MX2012001708A MX2012001708A MX2012001708A MX2012001708A MX2012001708A MX 2012001708 A MX2012001708 A MX 2012001708A MX 2012001708 A MX2012001708 A MX 2012001708A MX 2012001708 A MX2012001708 A MX 2012001708A MX 2012001708 A MX2012001708 A MX 2012001708A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- disease
- alzheimer
- oligomer
- bind
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 5
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940125644 antibody drug Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000007507 senile plaque formation Effects 0.000 abstract 1
- 208000022288 senile plaque formation Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describe un anticuerpo humanizado anti-oligómero de Aß que no se une a los monómeros de Aß y que solamente se une específicamente a los oligómeros de Aß; un agente anti-disfunción cognoscitiva, un agente para tratar la enfermedad de Alzheimer, un agente para suprimir la formación de placa neurítica y un inhibidor de la formación de fibra de amiloide Aß que comprende el anticuerpo como ingrediente activo; un método para por lo menos uno de prevención y tratamiento de la disfunción cognoscitiva o enfermedad de Alzheimer, que comprende la etapa de administrar el anticuerpo; y un método para suprimir la progresión de la enfermedad de Alzheimer, que comprende la etapa de administrar el anticuerpo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23203809P | 2009-08-07 | 2009-08-07 | |
| PCT/JP2010/063431 WO2011016568A1 (ja) | 2009-08-07 | 2010-08-06 | 抗アミロイドβオリゴマーヒト化抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012001708A true MX2012001708A (es) | 2012-05-22 |
Family
ID=43544461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001708A MX2012001708A (es) | 2009-08-07 | 2010-08-06 | Anticuerpo humanizado anti-oligomero de amiloide b. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8333967B2 (es) |
| EP (1) | EP2463368B1 (es) |
| JP (1) | JP5051806B2 (es) |
| KR (1) | KR101787118B1 (es) |
| CN (1) | CN102597234B (es) |
| AU (1) | AU2010279892B8 (es) |
| BR (1) | BR112012002819B1 (es) |
| CA (1) | CA2769464C (es) |
| DK (1) | DK2463368T3 (es) |
| ES (1) | ES2661601T3 (es) |
| HU (1) | HUE036392T2 (es) |
| MX (1) | MX2012001708A (es) |
| PL (1) | PL2463368T3 (es) |
| PT (1) | PT2463368T (es) |
| SG (1) | SG177679A1 (es) |
| WO (1) | WO2011016567A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2921180T3 (es) | 2014-04-16 | 2022-08-19 | Kyowa Kirin Co Ltd | Método para medir la toxicidad del CSF humano |
| BR112018013807A2 (pt) * | 2016-01-12 | 2018-12-11 | National University Corporation Chiba University | ?anticorpo anti-myl9? |
| CN107118260B (zh) * | 2017-05-12 | 2020-10-16 | 中国科学院过程工程研究所 | 一种多肽及其组成的疫苗和应用 |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EP3877399A4 (en) * | 2018-11-06 | 2022-10-19 | Alsatech, Inc. | CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN117586388A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 改进的β淀粉样蛋白寡聚体特异性结合抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| CA2205007C (en) | 1995-09-11 | 2010-12-14 | Masamichi Koike | Antibody against human interleukin-5 receptor .alpha. chain |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US20050059591A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP3690043A1 (en) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antibody composition-producing cell |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| CA2544692C (en) * | 2004-07-09 | 2014-04-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| JP3806883B2 (ja) | 2004-09-28 | 2006-08-09 | ダイキン工業株式会社 | 空気調和装置 |
| CN101137394A (zh) * | 2004-10-25 | 2008-03-05 | 默克制药公司 | 抗addl抗体及其应用 |
| JP5173426B2 (ja) * | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌ抗体およびこの使用 |
| WO2006075668A1 (ja) | 2005-01-12 | 2006-07-20 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG2およびIgG3抗体 |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| WO2009051220A1 (ja) | 2007-10-19 | 2009-04-23 | Immunas Pharma, Inc. | Aβオリゴマーに特異的に結合する抗体およびその利用 |
| ES2617604T3 (es) * | 2008-02-08 | 2017-06-19 | Immunas Pharma, Inc. | Anticuerpos capaces de unirse específicamente a oligómeros de beta amiloides, y su utilización |
| PT2581113T (pt) * | 2010-06-11 | 2018-07-04 | Univ Kyushu Nat Univ Corp | Anticorpo anti-tim-3 |
-
2010
- 2010-08-06 BR BR112012002819-7A patent/BR112012002819B1/pt active IP Right Grant
- 2010-08-06 PL PL10806566T patent/PL2463368T3/pl unknown
- 2010-08-06 EP EP10806566.5A patent/EP2463368B1/en active Active
- 2010-08-06 PT PT108065665T patent/PT2463368T/pt unknown
- 2010-08-06 KR KR1020127003173A patent/KR101787118B1/ko active Active
- 2010-08-06 CN CN201080035051.8A patent/CN102597234B/zh active Active
- 2010-08-06 AU AU2010279892A patent/AU2010279892B8/en active Active
- 2010-08-06 SG SG2012003208A patent/SG177679A1/en unknown
- 2010-08-06 DK DK10806566.5T patent/DK2463368T3/en active
- 2010-08-06 CA CA2769464A patent/CA2769464C/en active Active
- 2010-08-06 JP JP2011525961A patent/JP5051806B2/ja active Active
- 2010-08-06 ES ES10806566.5T patent/ES2661601T3/es active Active
- 2010-08-06 WO PCT/JP2010/063430 patent/WO2011016567A1/ja not_active Ceased
- 2010-08-06 MX MX2012001708A patent/MX2012001708A/es active IP Right Grant
- 2010-08-06 HU HUE10806566A patent/HUE036392T2/hu unknown
- 2010-08-09 US US12/852,548 patent/US8333967B2/en active Active
-
2012
- 2012-11-15 US US13/678,214 patent/US9181332B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769464A1 (en) | 2011-02-10 |
| RU2012108610A (ru) | 2013-09-20 |
| SG177679A1 (en) | 2012-02-28 |
| JP5051806B2 (ja) | 2012-10-17 |
| PL2463368T3 (pl) | 2018-07-31 |
| CN102597234B (zh) | 2014-10-29 |
| CN102597234A (zh) | 2012-07-18 |
| ES2661601T3 (es) | 2018-04-02 |
| BR112012002819B1 (pt) | 2022-11-22 |
| US8333967B2 (en) | 2012-12-18 |
| KR101787118B1 (ko) | 2017-10-18 |
| AU2010279892B2 (en) | 2014-05-22 |
| BR112012002819A2 (pt) | 2017-07-11 |
| AU2010279892B8 (en) | 2014-09-25 |
| US9181332B2 (en) | 2015-11-10 |
| PT2463368T (pt) | 2018-02-08 |
| EP2463368A9 (en) | 2012-11-28 |
| AU2010279892A8 (en) | 2014-09-25 |
| KR20120038474A (ko) | 2012-04-23 |
| CA2769464C (en) | 2017-11-21 |
| EP2463368A1 (en) | 2012-06-13 |
| US20130095526A1 (en) | 2013-04-18 |
| EP2463368A4 (en) | 2013-09-18 |
| DK2463368T3 (en) | 2018-01-22 |
| HUE036392T2 (hu) | 2018-07-30 |
| JPWO2011016567A1 (ja) | 2013-01-17 |
| US20120009179A1 (en) | 2012-01-12 |
| WO2011016567A1 (ja) | 2011-02-10 |
| EP2463368B1 (en) | 2018-01-10 |
| AU2010279892A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012001708A (es) | Anticuerpo humanizado anti-oligomero de amiloide b. | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2009050506A3 (en) | Combination 059 | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| ATE416177T1 (de) | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer | |
| WO2007027761A3 (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
| EA200901211A1 (ru) | Антигены белка с5 и их применение | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2010071826A3 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
| WO2008031835A3 (en) | Method of treating autoimmune diseases using vegf-pathway inhibitors | |
| TW200628473A (en) | Novel heterocycles | |
| EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| WO2008063311A3 (en) | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |